Healthcare & Life Sciences: The rise of a family office favorite industry

Healthcare as the second top industry: market dynamics and opportunities

Healthcare & Life Sciences ranks as the #2 sector for family office investments in 2025 with a 12% allocation. This placement is stable – not volatile. This shows long-term structural conviction.

The absolute investment volumes have even increased. The question is: Why is healthcare so attractive for family offices?

Structural reasons for healthcare focus

• Aging Populations: Global demographic reality: Population is aging, demand for healthcare services is increasing exponentially.
• Pandemic Legacy: Digital health, telehealth, remote monitoring – these categories are permanently established.
• AI in Healthcare: Diagnostics, drug discovery, treatment optimization – AI is revolutionizing healthcare.
• Regulatory barriers to entry: FOs like assets that are difficult to copy. Healthcare IP, approvals, regulations are real moats.
• Recession resilience: Healthcare is counter-cyclical. During recessions, health spending does not decline like other categories.

These factors add up to a perfect profile for FO Investo: Long-term megatrends + regulatory protection measures + stable cash flow.

Biotech research laboratory

Medical technology – MedTech innovations

Healthcare sub-sectors: Where FOs invest

Healthcare is broad. Where exactly are FOs concentrated?

• Pharma/Biotech (30%): Drug Development, particularly in specialized therapeutics (oncology, rare diseases, gene therapy)
• MedTech (25%): Medical Devices, Diagnostics, Surgical Instruments. High IP, recurring revenue potential.
• Digital Health (20%): Telemedicine, EHR systems, health analytics
• Healthcare Services (15%): Clinics, Rehabilitation Centers, Hospice Care – Operational FO particularly active
• Healthcare IT/Data (10%): Interoperability, data analytics, AI for health